These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28594844)

  • 21. Clinical Characteristics and prognostic analysis of Triple-negative Breast Cancer: Single institute experience.
    Maka VV; Pancha H; Shukla SN; Talati SS; Shah PM; Patel KM; Anand AS; Shah SA; Patel AA; Parikh S
    Gulf J Oncolog; 2016 Jan; 1(20):38-44. PubMed ID: 27050178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy.
    Qian J; Chen H; Ji X; Eisenberg R; Chakravarthy AB; Mayer IA; Massion PP
    Sci Rep; 2017 Apr; 7():45828. PubMed ID: 28387221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature.
    An X; Lei X; Huang R; Luo R; Li H; Xu F; Yuan Z; Wang S; de Nonneville A; Gonçalves A; Houvenaeghel G; Li J; Xue C; Shi Y
    Cancer; 2020 Aug; 126 Suppl 16():3837-3846. PubMed ID: 32710666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of Risk of Recurrence by Subtype in ≤ 1-cm Breast Tumors.
    Colonna SV; Higgins AK; Alvarez J; Saville BR; Lawrence J; Abramson VG
    Clin Breast Cancer; 2016 Jun; 16(3):223-31. PubMed ID: 26683741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value.
    Jiang YZ; Liu YR; Xu XE; Jin X; Hu X; Yu KD; Shao ZM
    Cancer Res; 2016 Apr; 76(8):2105-14. PubMed ID: 26921339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer.
    Lien MY; Liu LC; Wang HC; Yeh MH; Chen CJ; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Li LY; Lin PH; Chiu CF
    Anticancer Res; 2014 Dec; 34(12):7319-26. PubMed ID: 25503167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.
    Jacot W; Mollevi C; Fina F; Lopez-Crapez E; Martin PM; Colombo PE; Bibeau F; Romieu G; Lamy PJ
    BMC Cancer; 2015 Dec; 15():986. PubMed ID: 26680641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
    Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype.
    Kida K; Ishikawa T; Yamada A; Shimada K; Narui K; Sugae S; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Breast Cancer Res Treat; 2016 Apr; 156(2):261-9. PubMed ID: 26975188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
    Bahhnassy A; Mohanad M; Shaarawy S; Ismail MF; El-Bastawisy A; Ashmawy AM; Zekri AR
    Mol Med Rep; 2015 Jul; 12(1):851-64. PubMed ID: 25824321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
    Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
    Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
    Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
    Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.
    Buyukhatipoglu H; Babacan T; Kertmen N; Balakan O; Suner A; Ates O; Sarici F; Aslan A; Diker O; Tasdemir V; Ozisik Y; Altundag K
    J BUON; 2015; 20(1):22-7. PubMed ID: 25778291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of pN0 Triple-Negative Breast Cancer with or without Lymph Node Irradiation: A Single Institution Experience.
    Khalifa J; Duprez-Paumier R; Filleron T; Lacroix Triki M; Jouve E; Dalenc F; Massabeau C
    Breast J; 2016 Sep; 22(5):510-9. PubMed ID: 27261365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of triple-negative breast cancer radiosensitive gene signature and validation based on transcriptome analysis.
    Wushou A; Jiang YZ; Hou J; Liu YR; Guo XM; Shao ZM
    Breast Cancer Res Treat; 2015 Nov; 154(1):57-62. PubMed ID: 26476726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
    Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.